Caxton Corp reported 9 positions worth $1.62M for the quarter ended Jun 30, 2026, down 59.7% on the prior quarter. It opened 3 new positions, added to 2, trimmed 1 and exited 1. Its largest holding is Space Exploration Technologies Corp at 27.5% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| GLD Spdr Gold Trust | -7,623 | $3.28M | 81.5% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPCX Space Exploration Technologies Corp | Industrials | 2,606 | $445.35K | 27.48% | +2,606 | – | New | 0% |
| 2 | BRK-B Berkshire Hathaway Inc | Financial Services | 754 | $377.13K | 23.27% | +27 | +3.7% | Added | 0% |
| 3 | GOOGL Alphabet Inc. | Technology | 691 | $246.91K | 15.24% | +691 | – | New | 0% |
| 4 | BX Blackstone Inc. | Financial Services | 1,597 | $188.22K | 11.62% | +1,597 | – | New | 0% |
| 5 | KYTX Kyverna Therapeutics, Inc. | Healthcare | 12.3K | $110.01K | 6.79% | -6,426 | -34.2% | Reduced | 0.02% |
| 6 | LXEO Lexeo Therapeutics, Inc. | Healthcare | 17.0K | $78.96K | 4.87% | +3,019 | +21.7% | Added | 0.02% |
| 7 | XFOR X4 Pharmaceuticals, Inc | Healthcare | 15.6K | $72.65K | 4.48% | 0 | 0.0% | Unchanged | 0.01% |
| 8 | IKT Inhibikase Therapeutics, Inc. | Healthcare | 28.5K | $57.76K | 3.56% | 0 | 0.0% | Unchanged | 0.02% |
| 9 | ALXO Alx Oncology Holdings Inc | Healthcare | 20.9K | $43.36K | 2.68% | 0 | 0.0% | Unchanged | 0.02% |
Tip. Select a row to see that position’s full history at Caxton.
As of its Q2 2026 13F filing, Caxton Corp’s five largest positions were Space Exploration Technologies Corp (SPCX) at 27.5%, Berkshire Hathaway Inc (BRK-B) at 23.3%, Alphabet Inc. (GOOGL) at 15.2%, Blackstone Inc. (BX) at 11.6%, Kyverna Therapeutics, Inc. (KYTX) at 6.8% of the reported portfolio.
Caxton Corp reported a 13F portfolio worth $1.62M across 9 positions for Q2 2026. That is down 59.7% from the previous quarter.
Its largest purchases by value were Space Exploration Technologies Corp ($445.35K), Alphabet Inc. ($246.91K), Blackstone Inc. ($188.22K). It opened 3 new positions.
Its largest sales by value were Spdr Gold Trust ($3.28M), Kyverna Therapeutics, Inc. ($57.25K). It exited 1 positions entirely.
From the Form 13F-HR reports Caxton Corp files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.